SAN JOSE, Calif. , Sept. 26, 2024 /PRNewswire/ — Mendel AI, a leader in clinical artificial intelligence (AI), today announced the launch of its innovative Hypercube Platform, powered by Amazon Web Services (AWS). The platform allows healthcare organizations to leverage Mendel’s cutting-edge platform, built on AWS, to unlock insights from vast amounts of structured and unstructured clinical data, enhancing decision-making processes and optimizing patient care.
Mendel’s Hypercube Platform couples advanced large language models (LLMs) with a proprietary clinical hypergraph to deliver physician-level cognitive reasoning. By transforming fragmented data into meaningful clinical insights, healthcare organizations can accelerate research, streamline operations, and improve patient outcomes.
“We are excited to bring the full power of Mendel’s Hypercube Platform onto AWS,” said Dr. Karim Galil, CEO of Mendel AI. “By working with AWS, Mendel AI is helping healthcare organizations scale their clinical data workflows with ease and ensure data-driven, precise care delivery by utilizing Mendel’s clinically grounded AI agents. By leveraging the security, flexibility, and scalability of AWS, we’re empowering healthcare providers to unlock the potential of their data and improve care outcomes.”
Mendel’s Hypercube Platform offers a suite of tools designed to help healthcare organizations make better, data-driven decisions. Powered by AWS, users can gain access to a highly secure, scalable, and reliable infrastructure capable of handling the increasing complexity and volume of clinical data.
Customer Benefits
Healthcare organizations using Mendel’s Hypercube Platform powered by AWS will benefit from:
For more information on how Mendel AI is transforming clinical data workflows with AWS, visit Mendel AI.
About Mendel AI
Mendel AI supercharges clinical data workflows by coupling large language models with a proprietary clinical hypergraph, delivering scalable clinical reasoning without hallucinations and ensuring 100% explainability. Headquartered in San Jose, California, Mendel is backed by blue-chip investors, including Oak HC/FT and DCM.
For more information, visit www.mendel.ai or contact marketing@mendel.ai.
Media Contact: Jessica McNellis (jessica@galestrategies.com)
SOURCE Mendel
GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients…
TAMPA, Fla.--(BUSINESS WIRE)--#cryotherapy--Next Health, the world's most advanced brand of proactive healthcare centers, is bringing…
TORONTO, ON / ACCESSWIRE / September 27, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma…
Visit Covalon at booth 523 to discover the latest in compassionate vascular access solutions MISSISSAUGA,…
WASHINGTON & OXFORD, England--(BUSINESS WIRE)--#Healthcare--Perspectum announced two research studies that were recently published, bringing hope…
SHANGHAI, Sept. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading…